Mono Pharmacare's total inventories for the quarter that ended in Sep. 2025 was ₹516 Mil. Mono Pharmacare's average total inventories from the quarter that ended in Mar. 2025 to the quarter that ended in Sep. 2025 was ₹535 Mil.
In Ben Graham's calculation of Net-Net Working Capital, inventory is only considered worth half of its book value. Mono Pharmacare's Net-Net Working Capital per share for the quarter that ended in Sep. 2025 was ₹-7.48.
Days Inventory indicates the number of days of goods in sales that a company has in the inventory.
Mono Pharmacare's Days Inventory for the
six
months ended in Sep. 2025 was 158.01.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Mono Pharmacare's Inventory Turnover for the quarter that ended in Sep. 2025 was 1.15.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Mono Pharmacare's Inventory-to-Revenue for the quarter that ended in Sep. 2025 was 0.81.
Mono Pharmacare (NSE:MONOPHARMA) Total Inventories Explanation
Inventory control is an important part of business operation. If a company does not have enough inventory, it may not be able to meet customers' required delivery time. If it has too much inventory, the cost of holding the inventory can be high.
1. In Ben Graham's calculation of Net-Net Working Capital (NNWC), inventory is only considered worth half of its book value.
Mono Pharmacare's Net-Net Working Capital Per Share for the quarter that ended in Sep. 2025 is
4. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Mono Pharmacare's Inventory to Revenue for the quarter that ended in Sep. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
Manufacturers with durable competitive advantages have the advantage that the products they sell do not change, and therefore will never become obsolete. Buffett likes this advantage.
When identifying manufacturers with durable competitive advantage, look for inventory and net earnings that rise correspondingly. This indicates that the company is finding profitable ways to increase sales which called for an increase in inventory.
Manufacturers with inventories that spike up and down are indicative of competitive industries subject to boom and bust.
Mono Pharmacare Total Inventories Related Terms
Mono Pharmacare Total Inventories Historical Data
* Premium members only.
The historical data trend for Mono Pharmacare's Total Inventories can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Total Inventories includes the raw materials, work-in-process goods and completely finished goods of a company. It is a portion of a company's current assets.
Mono Pharmacare (NSE:MONOPHARMA) has a Total Inventories of ₹516 Mil as of Sep. 2025. The total amount of inventory as recorded on a company's balance sheet. View historical data for Mono Pharmacare and its competitors.
Is Mono Pharmacare's Total Inventories too high?
Mono Pharmacare's current Total Inventories is ₹516 Mil. Overall, Mono Pharmacare has a GF Score™ of 9/100, reflecting its overall financial health beyond just this single metric.
How does Mono Pharmacare's Total Inventories compare to competitors?
Mono Pharmacare's Total Inventories of ₹516 Mil can be compared against companies in the Healthcare Providers & Services industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Inventories for a Healthcare Providers & Services company?
A good Total Inventories depends on the Healthcare Providers & Services industry context. However, Total Inventories should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Inventories mean?
A high Total Inventories can signal that a stock is expensive relative to its fundamentals. The total amount of inventory as recorded on a company's balance sheet. View historical data for Mono Pharmacare and its competitors. Mono Pharmacare's current Total Inventories is ₹516 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Mono Pharmacare stock overvalued right now?
Mono Pharmacare (NSE:MONOPHARMA) has a current Total Inventories of ₹516 Mil. The current Total Inventories is ₹516 Mil. Mono Pharmacare's overall GF Score™ is 9/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Inventories calculated?
Total Inventories is calculated from a company's financial statements. For Mono Pharmacare (NSE:MONOPHARMA), the current Total Inventories is ₹516 Mil as of Sep. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Mono Pharmacare Ltd distributes a broad range of pharmaceutical products across India. Its portfolio includes antibiotics, antifungal medicines, cough and cold remedies, antacids, analgesics, nutraceuticals, skincare, antiseptics, cardiac and diabetic drugs, and cosmetic items. The company operates through contract manufacturing, sourcing products from various manufacturers and supplying them to healthcare providers and pharmacies. Revenue is generated through the sales and distribution of these pharmaceutical and healthcare products in the Indian market.
9GF Score
Get the complete analysis for NSE:MONOPHARMA
Total Inventories is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
NSE:MONOPHARMA has been successfully added to your 
